Is Ivosidenib a targeted drug?

Ivosidenib (Ivosidenib) belongs to a class of targeted therapy drugs. Specifically, it is an IDH1 inhibitor. IDH1 (isocitrate dehydrogenase 1) is an enzyme involved in cell metabolism. In some leukemias and other malignant tumors, the IDH1 gene may be mutated, leading to abnormal activation of the enzyme.

The mechanism of action of Ivonib is by inhibiting the abnormally activatedIDH1 enzyme, thereby slowing down or preventing the pathobiological process caused by this mutation. This targeting effect helps interfere with the growth and proliferation of cancer cells, precisely affecting cancer cells by targeting specific molecules or signaling pathways, and reducing damage to normal cells.

Targeted drugs have a more specific effect than traditional chemotherapy drugs because they specifically target specific molecules or biological processes in cancer cells. This allows targeted therapies to often be more effective at inhibiting tumor growth while reducing adverse effects on healthy cells.

For ivonib, it is mainly used to treat patients with acute myeloid leukemia (AML) who express IDH1 gene mutations, providing a targeted treatment option for this specific type of leukemia. However, it should be emphasized that each drug may have its specific indications and limitations of use, and patients should consult their physician before use to ensure a clear treatment plan and monitoring regimen.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.